Monitor the ASGCT presentation on May 14 for full data. Early signs of activity without preconditioning could de-risk the program, but sample is too small to draw conclusions. Expect volatility around the event.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 4 $3.83entry
- T+1 · 7mo ago +8.36%α +7.56% · $4.15
- T+5 · 6mo ago −0.26%α −3.20% · $3.82
- T+20 · 6mo ago −4.18%α −9.82% · $3.67
- T+60 · 4mo ago −31.59%α −33.45% · $2.62
Price Chart
How similar events traded
Executive Summary
Cabaletta Bio announced it will present new clinical and translational data from 4 refractory patients treated with rese-cel without preconditioning in the RESET-PV trial at ASGCT 2026. The data showed biologic activity in 2 of 4 patients and a favorable safety profile, but the sample is small and early-stage. No financial impact or guidance changes were disclosed.
Key Facts
- Data from 4 refractory pemphigus vulgaris patients receiving lowest-dose rese-cel without preconditioning will be presented at ASGCT on May 14, 2026.
- 2 of 4 patients demonstrated compelling clinical activity through 6 months; 3 of 4 remained off all immunomodulators and steroids.
- Complete peripheral B cell elimination observed in 3 of 4 patients; one Grade 1 CRS, no ICANS.
- Higher dose cohort in RESET-PV has been enrolled; durability data expected in H2 2026.
- Initial dose cohort of RESET-SLE (lupus) is fully enrolled; initial data expected in H1 2026.
Financial Impact
No financial figures disclosed; pre-revenue biotech.
Risk Factors
- Small sample size (n=4) limits statistical reliability.
- Early-stage data may not replicate in larger cohorts.
- No financial data or guidance provided; stock may move on sentiment alone.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-202389 |
| Document: 0001193125-26-202389-index-headers.html | 0001193125-26-202389 |
| Document: 0001193125-26-202389-index.html | 0001193125-26-202389 |
| Document: 0001193125-26-202389.txt | 0001193125-26-202389 |
Track record
29 reports on CABA
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +31.59% at T+60 after the May 4, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $1.15 Now $1.11 −3.09% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.32 Now $1.11 −15.91% settles Nov 23
- Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $1.33 Now $1.11 −16.54% settles Nov 19
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $1.45 Now $1.11 −23.45% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
- Nov 8, 20268d ago Press Release Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $1.28 to $1.33 Now $1.11 −13.28% ▲ +3.91% +0.62% vs SPY
- Nov 5, 202611d ago Press Release Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers